Milestone Pharmaceuticals Inc. MIST
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a cardio-renal-metabolic drug developer. Its lead program, CARDAMYST (etripamil) nasal spray, is in Phase 2 for Paroxysmal supraventricular tachycardia (PSVT). Its next catalyst on record is etripamil (AFib-RVR): Enroll first patient in Phase 3 registrational study (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: etripamil (AFib-RVR) — Enroll first patient in Phase 3 registrational study (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CARDAMYST (etripamil) nasal spray | PSVT | small molecule | Approved |
| etripamil nasal spray | Atrial fibrillation with rapid ventricular rate (AFib-RVR) | small molecule | Phase 2 |
Recent results and decisions
- Sep 3, 2026approval China NMPA approved etripamil nasal spray for PSVT, first approval outside the US; triggers $2.0M milestone (ex-US regulator).
China's National Medical Products Administration (NMPA) has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults.
Filing - Sep 3, 2026approval China's NMPA approves etripamil nasal spray for the treatment of PSVT in adults, marking the first regulatory approval of etripamil outside the United States.
China's National Medical Products Administration (NMPA) has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults.
Filing - Sep 3, 2026n/a NMPA approval triggers $2.0 million milestone payment to Milestone from Everest Medicines under the Greater China license agreement.
The NMPA decision marks the first regulatory approval of etripamil outside the United States and triggers a $2.0 million milestone payment to Milestone Pharmaceuticals.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.